Clinical trials: Memory Functions
Age-Related Memory Disorders
Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment
The purpose of the study is to determine the safety, tolerability, and effectiveness of 2 dose levels of LX6171 given over 28 days in patients with Age Associated Memory Impairment (AAMI).
- Trial name
- NCT00691808
- Testing
- LX6171 High Dose, LX6171 Low Dose
- Where
- 2 sites in Netherlands
- Volunteers
- 103 people
- Sponsor
- Lexicon Pharmaceuticals
Meningococcal Disease; Meningococcal Meningitis
Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine
The purpose of this study is to determine when a memory immune response after re-vaccination with Meningococcal C conjugate vaccine (Menjugate) or challenge with Meningococcal A/C polysaccharide vaccine can be observed, after…
- Trial name
- NCT00262015
- Testing
- · Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)
- Where
- United Kingdom
- Volunteers
- 264 people
- Sponsor
- Chiron Corporation
Dietary Supplement, Cognition
Nutritional Supplement's Effects on Cognition
This is a prospective, placebo controlled study, examining the effects of dietary supplement's effects on cognition and confirming safety.
- Conditions
- Dietary Supplement, Cognition, Healthy
- Trial name
- NCT05941949
- Testing
- Softgel Cognitive Formulation containing Astaxanthin, Grape Juice Extract and All Natural Vitamin E
- Where
- Australia
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Pharmanex
Schizophrenia, Schizoaffective
Frontal Gamma Coherence Neurofeedback for Patients With Schizophrenia
This preliminary, randomized, double-blind, placebo-controlled clinical trial will evaluate frontal gamma coherence neurofeedback in adults with schizophrenia.
- Trial name
- NCT07659938
- Testing
- Frontal gamma coherence neurofeedback
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BioSignal Solutions LLC
Alzheimer Disease, Cognition Disorders
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease…
- Trial name
- NCT00000174
- Testing
- Rivastigmine
- Where
- 15 sites in United States
- Sponsor
- Novartis
Mild Cognitive Impairment
BestBrain Evaluation of Cognitive Memory & Executive-Function
This study is intended 1. To quantify the effects of the iRemember personalized EEG-NFB therapy on working memory and executive functions in subjects with MCI by calculating the percentage of change in the Neurotrax tests…
- Trial name
- BECOME (NCT03954340)
- Testing
- iRemember Neurofeedback (NFB)
- Where
- Israel
- Volunteers
- 140 people
- Sponsor
- BestBrain Ltd.
Fatigue, Neoplasms
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients
To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.
- Trial name
- NCT00047476
- Testing
- dexmethylphenidate(d-mph)
- Where
- 21 sites in United States
- Volunteers
- 160 people
- Sponsor
- Celgene Corporation
Mood, Cognitive Performance
The Effects of A Proprietary Spearmint Extract on Cognitive Performance
This study was designed to evaluate the chronic effects of a proprietary spearmint extract over 90 days of supplementation on aspects of cognitive performance (cognitive function and active reaction time), subjective mood, and…
- Conditions
- Mood, Cognitive Performance, Sleep
- Trial name
- NCT02518165
- Testing
- Proprietary spearmint extract
- Where
- United States
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Kemin Foods LC
Agitation Associated With Alzheimer's Disease, Alzheimer's Type
Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo
To follow-up on the safety of subjects who were previously treated in a double-blind trial of brexpiprazole.
- Conditions
- Agitation Associated With Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
- Trial name
- NCT02192554
- Where
- 84 sites in United States, Bulgaria and 10 more
- Volunteers
- 450 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Alzheimer's Disease
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in…
- Trial name
- NCT01082965
- Testing
- Donepezil
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer
Memory Impairment, Age-related Cognitive Decline
Development of an Innovative Health Ingredient From Marine By-products for the Healthy Aging
This interventional, randomised, placebo-controlled and double-blind study aims to evaluate the effect of a dietary supplementation with a blue fish hydrolysate derived from marine by-products, containing peptides and n-3…
- Trial name
- BRAINBOOSTER (NCT04910399)
- Testing
- Blue fish hydrolysate
- Where
- 2 sites in France
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Abyss Ingredients
Hepatitis A, Hepatitis B
Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult
This study will evaluate the persistence of the immune response to HAV (hepatitis A virus) antigens and HBs (hepatitis B surface) antigens in healthy adults previously vaccinated with Twinrix Adult in the primary study, HAB-032…
- Trial name
- NCT01037114
- Testing
- Blood sampling, Engerix-B, Havrix
- Where
- Belgium
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Acute Effect of a Standardized Botanical Blend Rich in Polyphenols on Cognitive Functions in Healthy Students
Available literature suggests that flavanols-rich foods, and more especially monomeric flavanols-rich foods such as grape, can have an acute effect on cognitive functions via different mechanisms such as cerebral blood flow…
- Trial name
- NCT03508206
- Testing
- SBRP
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Activ'inside
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236574
- Testing
- Galantamine hydrobromide
- Volunteers
- 974 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Alzheimers Disease
Clinical Utility of Early vs. Late Blood Biomarker Testing for Alzheimer's Disease
The goal of this study is to evaluate whether use of the PrecivityAD2 blood biomarker assay with early result disclosure along with discretionary Precivity-ApoE proteotype testing will shorten the time to Alzheimer's Disease or…
- Trial name
- ADELAIDE (NCT06856681)
- Testing
- PrecivityAD2 - Early Testing, PrecivityAD2 - Delayed Testing
- Sponsor
- C2N Diagnostics
Memory Deficit Aquired Due to the Disease, e.g. Stroke, Neurodegeneration, Inflammatory Disease of CNS, Traumatic Brain Injury
Vestibular Stimulation in Sleep for Neurorehabilitation Patients
1. Why are we conducting this study? You are a patient of the neurorehabilitation clinic with one of the therapy focuses on memory and learning. Neuropsychological training is a standard therapeutic approach in this case.
- Trial name
- NCT07658027
- Testing
- Somnomat - rocking bed providing vestibular stimulation during sleep
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Cereneo AG
Alzheimer's Disease
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00093951
- Testing
- SGS742
- Where
- 59 sites in United States
- Volunteers
- 280 people
- Sponsor
- Saegis Pharmaceuticals
Cognitive Change, Mood
Turmeric for Memory Impairment and Cognition
The objective of the study is to test the capacity of acute and chronic supplementations of Turmipure GOLD® to improve cognitive performance in healthy aging
- Conditions
- Cognitive Change, Mood, Stress
- Trial name
- TURMEMIC (NCT04860050)
- Testing
- Turmipure Gold®
- Where
- Ireland
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- Givaudan France Naturals
Dementia, Mild Cognitive Impairment
Prospective Research in Memory Clinics (PRIME)
The purpose of the PRIME Study is to examine the current management and outcomes of patients with mild cognitive impairment or dementia.
- Trial name
- NCT00297271
- Testing
- Current treatment practice of each participating physician
- Where
- 9 sites in Australia
- Volunteers
- 970 people
- Sponsor
- Janssen-Cilag Pty Ltd
Mild Cognitive Impairment, Mild Dementia
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Associated With Parkinson's Disease or Prodromal or Manifest Lewy Body Dementia
- Conditions
- Mild Cognitive Impairment, Mild Dementia, Parkinson Disease, Lewy Body Disease
- Trial name
- NCT04148391
- Testing
- NYX-458
- Where
- 26 sites in United States
- Volunteers
- 99 people
- Sponsor
- Aptinyx